In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

Among adults with relapsing MS who received ublituximab, the annualized relapse rate continued to drop with up to 5 years of ...

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

Symptoms and frequency of relapses vary widely from person to person with the most common form of multiple sclerosis — and doctors aren’t entirely sure why. But, what exactly does a relapse look like?

Disease-modifying treatments (DMTs) are the gold standard of multiple sclerosis (MS) therapy. They’ve been extensively researched, leading to an evidence base substantiating their efficacy through ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...

MS is due to the body’s defence system, or immune system, attacking the insulating cover of myelin that protects the nerves. This damages the nerves and impairs their ability to pass on electric ...

Multiple sclerosis is a disorder of the immune system, where the myelin coating the nerve cells is damaged by antibodies formed by the defence system of the body. This affects the functioning of the ...